Carregant...
Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3
Cancer progression depends on stepwise accumulation of oncogenic mutations and a select group of growth factors essential for tumor growth, metastasis and angiogenesis. Agents blocking the epidermal growth factor receptor (EGFR, also called HER1 and ERBB1) and the co-receptor called HER2/ERBB2 have...
Guardat en:
| Publicat a: | Hum Vaccin Immunother |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Taylor & Francis
2015
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4964743/ https://ncbi.nlm.nih.gov/pubmed/26529100 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2015.1102809 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|